Group 1 - The company Tianjin Development (00882) announced a financial agreement with Industrial Bank for a structured deposit [1] - The agreement involves an investment of RMB 70 million, equivalent to approximately HKD 76.5864 million [1] - This marks the 10th financial agreement between the company’s indirect non-wholly owned subsidiary, Lifescience Pharmaceutical (002393), and Industrial Bank [1]

证券代码：002393 证券简称：力生制药 公告编号：2025-061 天津力生制药股份有限公司 关于使用闲置募集资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 天津力生制药股份有限公司（以下简称"公司"）于2025年3月19日召开第七届董事会第 五十次会议、2025年4月11日召开2024年度股东大会，审议通过了《关于公司2025年使用 闲置募集资金进行现金管理额度的议案》，同意公司在不影响募集资金投资项目实施的情 况下，使用额度不超过人民币6亿元闲置募集资金购买安全性高、流动性好、由募集户银行 （招商银行、兴业银行或邮储银行）发行的短期理财产品，期限不超过股东大会批准之日 起12个月，在上述额度及期限范围内资金滚动使用。针对上述事项，公司保荐机构发表了 明确的同意意见。具体内容详见公司于2025年3月21日在巨潮资讯网(www.cninfo.com.cn） 披露的《关于公司2025年使用闲置募集资金进行现金管理额度的公告》（公告编号： 2025-025）及《渤海证券关于天津力生制药股份有限公司使用闲置募集资金购买理财产品 的核查 ...

Meeting Overview - The shareholder meeting was held on September 8, 2025, combining on-site and online voting methods [4][5][7] - The total share capital of the company as of the registration date was 257,704,999 shares, with 1,439,980 shares in the repurchase account not entitled to vote, resulting in 256,265,019 shares eligible for voting [5][6] Voting Results - No proposals were rejected during the meeting [1][2] - The controlling shareholder, Tianjin Jinhao Pharmaceutical Co., Ltd., abstained from voting on Proposal 1, with 131,194,851 shares involved [8] - Proposals 2, 5, and 6 were special resolutions that received over two-thirds approval from the voting shareholders and their authorized representatives [8] Legal Compliance - The meeting complied with relevant laws, regulations, and the company's articles of association, as confirmed by the legal opinions provided by Tianjin Sifang Junhui Law Firm [8][9]

渤海证券股份有限公司 关于 天津力生制药股份有限公司 调整 2024 年限制性股票激励计划 证券简称：力生制药 证券代码：002393 回购价格暨回购注销部分激励对象已获授 但尚未解除限售的限制性股票事项 之 独立财务顾问报告 | 第一章 | 释义 | 2 | | --- | --- | --- | | 第二章 | 声明 | 3 | | 第三章 | 基本假设 | 4 | | 第四章 | 激励计划履行的相关审批程序 5 | | | 第五章 | 本次激励股份回购价格调整的具体情况 7 | | | 第六章 | 本次回购注销情况 | 8 | | 第七章 | 独立财务顾问意见 | 9 | | 第八章 | 备查文件 | 9 | 第一章 释义 以下词语如无特殊说明，在本文中具有如下含义： | 力生制药、本公司、 | 指 | 天津力生制药股份有限公司 | | --- | --- | --- | | 公司 | | | | 渤海证券、独立财务 | | | | 顾问、本独立财务顾 | 指 | 渤海证券股份有限公司 | | 问 | | | | | | 《渤海证券股份有限公司关于天津力生制药股份有限公司调整 | | 独立财务顾问报告 ...

证券简称：力生制药 证券代码：002393 渤海证券股份有限公司 关于 天津力生制药股份有限公司 调整 2022 年限制性股票激励计划回购价格 暨回购注销部分激励对象已获授但尚未解除限售的 限制性股票事项 之 独立财务顾问报告 独立财务顾问 签署日期：二〇二五年九月 | | | | 第一章 释义 . | | --- | | 第二章 声明 . | | 第三章 基本假设 . | | 第四章 激励计划履行的相关审批程序 . | | 第五章 本次激励股份回购价格调整的具体情况 | | 第六章 本次回购注销情况 . | | 第七章 独立财务顾问意见 . | | 第八章 备查文件 | 第一章 释义 以下词语如无特殊说明，在本文中具有如下含义： | 力生制药、本公司、公司 | 指 | 天津力生制药股份有限公司 | | --- | --- | --- | | 渤海证券、独立财务顾 问、本独立财务顾问 | 指 | 渤海证券股份有限公司 | | | | 《渤海证券股份有限公司关于天津力生制药股份有限公 | | 独立财务顾问报告 | 指 | 司调整 2022 年限制性股票激励计划回购价格暨回购注销 部分激励对象已获授但尚未解除限售 ...

关于 天津力生制药股份有限公司2025年第二次临时股东会 之 法律意见书 天津市四方君汇律师事务所 Join & High Law Office 关于天津力生制药股份有限公司 2025 年第二次临时股东会之法律意见书 致：天津力生制药股份有限公司 天津四方君汇律师事务所（以下简称"本所"）接受天津力生制药股份有限公司（以下简 称"公司"）委托，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上市公 司股东会规则》（以下简称"《股东会规则》"）等法律、法规和其他规范性文件（以下简称 "法律、法规"）以及《天津力生制药股份有限公司章程》（以下简称"《公司章程》"）有 关规定，就公司召开 2025 年第二次临时股东会（以下简称"本次股东会"）有关事宜出具本 法律意见书。 本法律意见书仅就本次股东会的召集和召开程序、出席本次股东会人员的资格、召集人资 格、会议表决程序是否符合法律、法规及《公司章程》规定，以及表决结果是否合法有效发表 意见，并不对本次股东会所审议的议案内容以及该等议案所表述的相关事实的真实性、准确性 或合法性发表意见。 为出具本法律意见书，本所律师审查了本次股东会相关的文件、资料，并对本次股 ...

2025年第二次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 证券代码：002393 证券简称：力生制药 公告编号：2025-060 天津力生制药股份有限公司 特别提示： 1.本次股东会未出现否决提案的情形。 2.本次股东会未涉及变更以往股东会已通过的决议。 1．会议召开时间 （1）现场会议：2025年09月08日（星期一）下午2:40开始 （2）网络投票：2025年09月08日（星期一） 其中通过深圳证券交易所交易系统进行网络投票的具体时间为2025年09月08日上午 9:15—9:25,9:30—11:30和13:00—15:00；通过深圳证券交易所互联网投票系统进行网络 投票的具体时间为2025年09月08日9:15～15:00期间的任意时间。 2．会议召开地点：天津力生制药股份有限公司会议室 天津市西青经济技术开发区赛达北一道16号 3．会议方式：本次股东会采取现场投票与网络投票相结合的方式 3.本次股东会采取现场投票、网络投票相结合的方式召开。 一、会议召开和出席情况 （一）会议召开情况 | 1.总体出席情况 | 196 | 1 ...

Core Viewpoint - The company has received approval for its self-developed potassium chloride sustained-release tablets, which are expected to enhance its product portfolio and market share in the pharmaceutical industry [1][3]. Group 1: Product Approval and Characteristics - The potassium chloride sustained-release tablets have been approved by the National Medical Products Administration, with specifications of 0.5g and 0.6g [1]. - This product is classified as a Category 3 generic drug under new chemical drug registration, which is considered equivalent to passing the consistency evaluation [1]. - The sustained-release technology offers advantages such as improved medication adherence, stable blood drug concentration, reduced peak-trough fluctuations, and minimized side effects [1]. Group 2: Research and Development Achievements - The company has developed unique large-scale production technology for the potassium chloride sustained-release tablets, ensuring stable production and high efficiency [2]. - The research institute has successfully demonstrated bioequivalence between the new product and the original formulation, achieving consistent therapeutic effects [2]. - The company has also secured a patent for the preparation method of the potassium chloride sustained-release tablets, marking a breakthrough in core technology [2]. Group 3: Market Potential - The potassium chloride sustained-release tablets are included in the 2024 National Medical Insurance Directory, indicating significant market potential [2]. - Sales figures for the potassium chloride sustained-release tablets are projected to grow from 350 million yuan in 2022 to 400 million yuan in 2024 [2]. Group 4: Strategic Direction - The potassium chloride sustained-release tablets represent an upgrade to the company's existing product line, aimed at capturing a larger market share and generating greater benefits [3]. - The company plans to continue enhancing research and industrial collaboration to provide accessible quality medications for patients while creating long-term value for investors [3].

Group 1 - The core viewpoint of the article highlights the growth in the number of enterprises in the chemical raw materials and chemical products manufacturing industry, which increased by 1,021 to a total of 26,860 enterprises in the first half of 2025, representing a year-on-year growth of 3.95% [1] - The proportion of chemical raw materials and chemical products manufacturing enterprises in the total industrial enterprises is 5.16% [1] - The report referenced is the "2025-2031 China Basic Chemical Raw Materials Industry Market Supply and Demand Situation and Investment Prospects Analysis Report" published by Zhiyan Consulting [1] Group 2 - The data indicates that the threshold for scale industrial enterprises has been raised from an annual main business income of 5 million yuan to 20 million yuan since 2011 [1] - Zhiyan Consulting is recognized as a leading industry consulting agency in China, providing comprehensive industry research reports, business plans, feasibility studies, and customized services [1] - The consulting firm emphasizes its commitment to delivering quality services and market insights to empower investment decisions [1]

Core Viewpoint - The company, Lisheng Pharmaceutical, has received drug registration certificates from the National Medical Products Administration for its potassium chloride sustained-release tablets in two specifications: 0.5g and 0.6g [1]. Group 1 - The company announced the receipt of the drug registration certificate for potassium chloride sustained-release tablets 0.5g (Batch No: 2025S02514) [1] - The company also received the drug registration certificate for potassium chloride sustained-release tablets 0.6g (Batch No: 2025S02515) [1] - Both products have successfully passed the drug marketing license application [1]